News & events.

Our news.

Filter by Category
Filter by Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
News
February 10, 2022
2022

Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments

Read article
Event
February 10, 2022
2022

PEGS Boston 2022

Read article
Event
February 10, 2022
2022

Gordon Research Conference: Antibody Biology and Engineering 2022

Read article
Event
February 8, 2022
2022

Festival of Biologics USA 2022

Read article
News
January 27, 2022
2022

AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

Read article
News
January 9, 2022
2022

AbCellera’s statement on the neutralization activity of its monoclonal antibody therapies against the Omicron variant of concern

Read article
News
December 7, 2021
2021

AbCellera Announces Changes to Its Board of Directors

Read article
News
December 3, 2021
2021

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12

Read article
News
December 2, 2021
2021

AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

Read article
News
November 4, 2021
2021

AbCellera Announces Virtual Presentations at Investor Conferences in November

Read article